相关实验视频

Updated: Sep 11, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

对接受Tagraxofusp的囊性血类树突细胞瘤患者的护理优化

Karolina Faysman¹, Joelle Rubin², Amber Lubas³

¹From UCLA Medical Center, Los Angeles, California.

Journal of the advanced practitioner in oncology

|August 11, 2025

概括

塔格拉克索弗斯普是一种针对布拉斯性血细胞状树突细胞瘤 (BPDCN) 的向治疗. 这种治疗在BPDCN患者中显示出持久的反应,使许多人能够接受干细胞移植.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

囊性血细胞状树突细胞瘤 (BPDCN) 是一种具有攻击性的血液性恶性瘤.
BPDCN表达CD123并且通常影响皮肤,骨髓,血液和内脏.
Tagraxofusp是美国唯一批准的针对BPDCN的CD123向疗法.

研究的目的:

审查使用tagraxofusp治疗的BPDCN患者管理的最佳实践.
突出高级从业人员 (AP) 在tagraxofusp治疗中的作用.
为了使临床管理与美国包装插件和现实世界AP方法保持一致.

主要方法:

一个关键的,多中心的,第二阶段研究 (NCT02113982) 的tagraxofusp单一治疗的审查.
分析tagraxofusp在治疗先导和复发/耐药BPDCN中的疗效.
纳入高级实践者 (AP) 对患者监测和支持性护理的观点.

主要成果:

在Tagraxofusp单一治疗中,在BPDCN中表现出持久的临床反应.
许多患者在tagraxofusp诱导的缓解后进行干细胞移植.
药剂师在监测,管理不良事件和患者教育方面发挥着至关重要的作用.

结论:

Tagraxofusp是一种有效的治疗BPDCN,促进干细胞移植.
优化tagraxofusp治疗涉及一个专门的跨学科团队和AP领导的管理.
最佳实践强调全面的患者护理,包括AP的监测和支持性管理.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...